Rapid Micro Biosystems Secures Multi-System Growth Direct Order from Samsung Biologics
Rapid Micro Biosystems won a follow-on multi-system order from Samsung Biologics for its Growth Direct platform, marking further expansion of automated microbial quality control across Samsung’s manufacturing network. The deal supports Samsung’s integrated plant design with faster time-to-result, stronger data integrity and higher throughput for critical healthcare product release.
1. Order Details
Rapid Micro Biosystems received an undisclosed multi-system purchase order from Samsung Biologics to expand its Growth Direct automation platform. This follow-on order builds on an existing agreement aimed at automating microbial quality control workflows in Samsung’s global CDMO facilities.
2. Partnership Significance
The order underscores deepening collaboration between the two companies, positioning Rapid Micro Biosystems as a key technology provider for one of the largest contract development and manufacturing organizations. Strengthened ties may pave the way for further system deployments and service agreements.
3. Growth Direct Platform Benefits
The Growth Direct system brings microbial quality control analysis directly to the manufacturing floor, delivering faster time-to-result, higher accuracy and robust data integrity. These enhancements help accelerate batch release decisions and support scalable, next-generation biologics and vaccine production.